Cullinan Therapeutics, Inc.
CGEM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001789972
In the last 90 days, Cullinan Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 183 institutions reported holding it in 13F filings for Q2 2026, worth $1.30B in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Cullinan Therapeutics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 106
- 0 vs. Q2 2023
- Shares held
- 38.0M
- +1.13M (+3.1%) vs. Q2 2023
- Total value
- $344.0M
- −$53.3M (−13.4%) vs. Q2 2023
- New holders
- 13
- 33 more added
- Sold out
- 13
- 31 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CGEM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 183 | $1.30B |
| Q1 2026 | 174 | $931.0M |
| Q4 2025 | 153 | $653.8M |
| Q3 2025 | 145 | $362.2M |
| Q2 2025 | 144 | $471.4M |
| Q1 2025 | 149 | $489.6M |
| Q4 2024 | 147 | $798.8M |
| Q3 2024 | 137 | $1.09B |
| Q2 2024 | 135 | $1.10B |
| Q1 2024 | 113 | $670.8M |
| Q4 2023 | 113 | $375.6M |
| Q3 2023 | 106 | $344.0M |
| Q2 2023 | 106 | $397.3M |
| Q1 2023 | 103 | $329.5M |
| Q4 2022 | 97 | $397.7M |
| Q3 2022 | 100 | $474.7M |
| Q2 2022 | 89 | $481.7M |
| Q1 2022 | 82 | $386.3M |
| Q4 2021 | 75 | $559.7M |
| Q3 2021 | 66 | $762.3M |
| Q2 2021 | 71 | $828.5M |
| Q1 2021 | 70 | $1.30B |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Cullinan Therapeutics, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Braidwell LP | 1,908,865 | $17.3M | 0.55% | 00.0% | Unchanged |
| BlackRock Inc. | 2,236,285 | $20.2M | 0.00% | +132,216+6.3% | Added |
| Franklin Resources Inc | 2,890,775 | $26.2M | 0.01% | +556,689+23.9% | Added |
| BVF Inc | 3,196,701 | $28.9M | 0.78% | 00.0% | Unchanged |
| CHI Advisors LLC | 3,414,189 | $30.9M | 12.26% | 00.0% | Unchanged |
| MPM Oncology Impact Management LP | 7,648,268 | $69.2M | 18.48% | 00.0% | Unchanged |
| Artal Group S.A. | 0 | $0 | 0.00% | −250,000−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −187,547−100.0% | Sold out |
| Lynx1 Capital Management LP | 0 | $0 | 0.00% | −115,063−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −83,745−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −28,495−100.0% | Sold out |
| Russell Investments Group, Ltd. | 0 | $0 | 0.00% | −21,784−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −10,837−100.0% | Sold out |
| Public Employees Retirement System of Ohio | 0 | $0 | 0.00% | −4,900−100.0% | Sold out |
| Gladius Capital Management LP | 0 | $0 | 0.00% | −2,578−100.0% | Sold out |
| Ancora Advisors, LLC | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −154−100.0% | Sold out |
| Red Tortoise LLC | 0 | $0 | 0.00% | −140−100.0% | Sold out |
| Allworth Financial LP | 0 | $0 | 0.00% | −31−100.0% | Sold out |